Showing results (431-440 of 667) with videos related to

Sort By:
Pageof 67
Journal of Lipid Research|May 31, 2023
Equivalent carbon number-based targeted odd-chain fatty acyl lipidomics reveals triacylglycerol profiling in clinical colon cancerJiangang Zhang, Shuai Yang, Jingchun Wang, et al.
Briefings in Bioinformatics|October 16, 2016
Combinatorial epigenetic regulation of non-coding RNAs has profound effects on oncogenic pathways in breast cancer subtypesJuan Xu, ZiShan Wang, Shengli Li, et al.
Journal of Cancer Research and Clinical Oncology|March 13, 2019
Retraction Note to: SOX2 oncogenes amplified and operate to activate AKT signalling in gastric cancer and predict immunotherapy responsivenessYajun Tian, Xin Jia, Shengxiang Wang, et al.
Biomaterials Science|March 21, 2019
Facile synthesis of organosilica-capped mesoporous silica nanocarriers with selective redox-triggered drug release properties for safe tumor chemotherapyLuying Shen, Shan Pan, Dechao Niu, et al.
Journal of Materials Chemistry. B|April 9, 2020
Preparation of an rhBMP-2 loaded mesoporous bioactive glass/calcium phosphate cement porous composite scaffold for rapid bone tissue regenerationNan Li, Chuan Jiang, Xingdi Zhang, et al.
BMC Immunology|April 18, 2020
Thalidomide with blockade of co-stimulatory molecules prolongs the survival of alloantigen-primed mice with cardiac allograftsMaoshu Zhu, Yunhan Ma, Kai Tan, et al.
British Journal of Cancer|June 1, 2024
DYNLL1 accelerates cell cycle via ILF2/CDK4 axis to promote hepatocellular carcinoma development and palbociclib sensitivityYuechen Liu, Zhenkang Li, Jinchao Zhang, et al.
Nature Communications|April 5, 2018
Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancersDaniel J McGrail, Lorenzo Federico, Yongsheng Li, et al.
Iscience|June 16, 2025
Anti-OX40 antibody BAT6026 in patients with advanced solid tumors: A multi-center phase I studyHuaqiang Zhou, Yuxiang Ma, Yongsheng Li, et al.
BMJ Open|February 28, 2023
Afatinib in combination with GEMOX chemotherapy as the adjuvant treatment in patients with ErbB pathway mutated, resectable gallbladder cancer: study protocol for a ctDNA-based, multicentre, open-label, randomised, controlled, phase II trialMao Yang, Yuhao Zhao, Yongsheng Li, et al.
Pageof 67